Reduction of baclofen-, but not sodium valproate-induced growth hormone release in type I diabetic men.
The effects of sodium valproate (a drug enhancing endogenous gamma aminobutyric acid (GABA)-ergic activity) and of the GABA analog baclofen (a GABA B receptor agonist) on serum GH levels was tested in 8 type I diabetic men and 8 normal controls. Sodium valproate (800 mg) or baclofen (10 mg) were given by mouth at 08.30 h on the experimental day. Control tests with a placebo were performed on different occasions. Basal GH levels were similar in controls and diabetic patients. Sodium valproate induced a 7 fold increase in serum GH concentrations in both groups. In contrast, baclofen-induced GH rise was significantly higher in normal controls (mean peak was 3.4 times higher than baseline) than in diabetic patients (mean peak was only 2.1 times higher than basal value). Serum GH levels did not change after placebo administration in any groups. These data suggest the presence of diabetes-induced alterations of a GABAergic pathway mediated by B receptors in the control of GH secretion. Alternatively, the data might indicate a change in diabetic men of other baclofen-sensitive neurotransmissions, different from GABA.
Coiro
V
V
Cattedra di Clinica Medica Generale, Università di Parma, Italy.
Capretti
L
L
Bianconi
L
L
Castelli
A
A
Cerri
L
L
Roberti
G
G
Marcato
A
A
Volpi
R
R
Chiodera
P
P
D000328:Adult; D001418:Baclofen / Q000494:pharmacology*; D003922:Diabetes Mellitus, Type 1 / Q000503:physiopathology*; D013006:Growth Hormone / Q000378:metabolism*; D006801:Humans; D008297:Male; D011963:Receptors, GABA-A / Q000187:drug effects / Q000502:physiology; D014635:Valproic Acid / Q000494:pharmacology*; D005680:gamma-Aminobutyric Acid / Q000502:physiology*
D011963:Receptors, GABA-A; D005680:gamma-Aminobutyric Acid; D014635:Valproic Acid; D013006:Growth Hormone; D001418:Baclofen